Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

114 trials

NCT06450041
Recruiting
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · United States · 13 sites
Registry update: 20 Jul 2026
NCT06836505
Recruiting
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Phase 1/2 · China · 3 sites
Registry update: 26 Feb 2025
NCT06540963
Recruiting
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase 2 · United States · 12 sites
Registry update: 3 Sept 2026
NCT06684639
Recruiting
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
Early phase 1 · China · 1 site
Registry update: 20 Dec 2024
NCT06988475
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Phase 2/3 · United Kingdom · 17 sites
Registry update: 24 Nov 2025
2022-501694-39-01
Recruiting
mFBG PET-CT for neuroblastoma
Phase 1/2 · Netherlands · 1 site
Registry update: 16 Oct 2025
NCT07334301
Recruiting
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Phase 1/2 · Austria, Australia, Belgium, Germany, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Norway, New Zealand, Sweden · 69 sites
Registry update: 12 Jan 2026
NCT06674265
Recruiting
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Phase 1 · Iran · 1 site
Registry update: 9 Apr 2025
NCT06631391
Recruiting
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
Phase 1 · China · 1 site
Registry update: 20 Feb 2025
NCT06541262
Recruiting
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 · Canada, United States · 24 sites
Registry update: 6 Oct 2026
NCT06607692
Recruiting
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Phase 1/2 · Spain · 1 site
Registry update: 4 Jun 2026
NCT06395103
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Phase 1/2 · Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Hungary, Israel, Italy, South Korea, Netherlands, Sweden, Slovakia, Taiwan, United States · 72 sites
Registry update: 30 Oct 2026
NCT06528496
Recruiting
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 · United States · 1 site
Registry update: 28 Aug 2026
NCT06500819
Recruiting
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · United States · 1 site
Registry update: 7 May 2026
NCT06818916
Recruiting
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Not applicable · China · 1 site
Registry update: 3 Dec 2025
NCT06041516
Recruiting
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Phase 1 · United States · 1 site
Registry update: 9 Nov 2026
NCT06574698
Recruiting
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
Not applicable · China · 1 site
Registry update: 28 Aug 2024
NCT06172296
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Phase 3 · Australia, Canada, New Zealand, Puerto Rico, United States · 180 sites
Registry update: 30 Oct 2026
2022-501725-21-00
Recruiting
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Phase 1 · Germany · 4 sites
Registry update: 31 Aug 2026
NCT06176989
Recruiting
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 · United States · 1 site
Registry update: 5 Nov 2026

Ordered by registry start date. Freshness and sponsorship never change the order.